Shattuck Labs closed at $5.15 on Nov 4, down 5.85%, 36.1% below its 52-week closing high. Volume of 871.0K shares was 0.84× its 20-day average (close to normal).
Split-adjusted performance: -12.1% over one month, -22.9% over six months, +158.8% over one year.
Short interest was 10.4M shares at the Oct 15 settlement, down 4.6% from the prior report (13.2% of float, 7.2 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| STTKShattuck Labs | $5.15 | −5.85% | −22.9% | — | — | — | $516.9M | |
| FTHFaeth Therapeutics | $19.99 | +1.73% | — | — | — | — | $516.6M | Compare |
| CAPRCapricor Therapeutics | $8.92 | +8.25% | −74.1% | — | — | — | $518.6M | Compare |
| CBIOCrescent Biopharma | $13.82 | +5.82% | −23.5% | — | — | — | $513.4M | Compare |
| CTMXCytomX Therapeutics | $2.35 | +7.80% | −43.1% | −92.4% | −1457.4% | — | $512.1M | Compare |
| OVIDOvid Therapeutics | $2.74 | +14.17% | −1.4% | −88.3% | −2047.6% | — | $535.1M | Compare |
| CLYMClimb Bio | $9.33 | −4.31% | −23.6% | — | — | — | $535.9M | Compare |
| EOLSEvolus | $7.47 | +1.36% | +18.2% | +21.2% | −9.6% | — | $493.4M | Compare |
| MNPRMonopar Therapeutics | $72.81 | +4.18% | +14.0% | — | — | — | $488.7M | Compare |
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
